---
figid: PMC9562258__cancers-14-04863-g001
figtitle: BRAF Inhibitors in Non-Small Cell Lung Cancer
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9562258
filename: cancers-14-04863-g001.jpg
figlink: /pmc/articles/PMC9562258/figure/cancers-14-04863-f001/
number: F1
caption: BRAF pathway and its inhibition. Under physiological conditions, BRAF activation
  strictly depends on RAS-GTP binding forms. Once activated, RAF isoforms create either
  homo- or heterodimers, eventually leading to the phosphorylation of MEK 1/2 and
  their downstream pathway. Conversely, BRAF class I mutations can directly activate
  downstream MEK 1/2 in an RAS-independent manner, resulting in deregulated proliferation
  and survival. BRAF inhibitors (dabrafenib, trametinib and encorafenib) combined
  with MEK inhibitors (trametinib, cobimetinib and binimetinib) eventually hinder
  downstream signalling.
papertitle: BRAF Inhibitors in Non-Small Cell Lung Cancer.
reftext: Vincenzo Sforza, et al. Cancers (Basel). 2022 Oct;14(19):4863.
year: '2022'
doi: 10.3390/cancers14194863
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: NSCLC | BRAF | MEK | dabrafenib | trametinib | encorafenib | binimetinib
automl_pathway: 0.9659601
figid_alias: PMC9562258__F1
figtype: Figure
redirect_from: /figures/PMC9562258__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9562258__cancers-14-04863-g001.html
  '@type': Dataset
  description: BRAF pathway and its inhibition. Under physiological conditions, BRAF
    activation strictly depends on RAS-GTP binding forms. Once activated, RAF isoforms
    create either homo- or heterodimers, eventually leading to the phosphorylation
    of MEK 1/2 and their downstream pathway. Conversely, BRAF class I mutations can
    directly activate downstream MEK 1/2 in an RAS-independent manner, resulting in
    deregulated proliferation and survival. BRAF inhibitors (dabrafenib, trametinib
    and encorafenib) combined with MEK inhibitors (trametinib, cobimetinib and binimetinib)
    eventually hinder downstream signalling.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GRB2
  - PTPN11
  - BRAF
  - KRAS
  - NRAS
  - ARAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
---
